NASDAQ:VKTX - Viking Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $9.95 -0.91 (-8.38 %) (As of 07/18/2018 08:00 AM ET)Previous Close$10.86Today's Range$9.82 - $10.8852-Week Range$0.88 - $13.43Volume3.32 million shsAverage Volume2.35 million shsMarket Capitalization$658.69 millionP/E Ratio-12.59Dividend YieldN/ABeta2.78 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California. Receive VKTX News and Ratings via Email Sign-up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:VKTX CUSIPN/A Webwww.vikingtherapeutics.com Phone858-704-4660 Debt Debt-to-Equity RatioN/A Current Ratio12.44 Quick Ratio12.44 Price-To-Earnings Trailing P/E Ratio-12.59 Forward P/E Ratio-23.14 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$0.38 per share Price / Book26.18 Profitability EPS (Most Recent Fiscal Year)($0.79) Net Income$-20,570,000.00 Net MarginsN/A Return on Equity-79.70% Return on Assets-59.44% Miscellaneous Employees14 Outstanding Shares60,650,000Market Cap$658.69 Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions What is Viking Therapeutics' stock symbol? Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX." How were Viking Therapeutics' earnings last quarter? Viking Therapeutics Inc (NASDAQ:VKTX) announced its earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.02. View Viking Therapeutics' Earnings History. When is Viking Therapeutics' next earnings date? Viking Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Viking Therapeutics. What price target have analysts set for VKTX? 6 equities research analysts have issued 12-month target prices for Viking Therapeutics' shares. Their predictions range from $13.00 to $15.00. On average, they expect Viking Therapeutics' stock price to reach $14.40 in the next year. This suggests a possible upside of 44.7% from the stock's current price. View Analyst Ratings for Viking Therapeutics. What is the consensus analysts' recommendation for Viking Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Viking Therapeutics? Viking Therapeutics saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 9,698,446 shares, an increase of 57.6% from the June 15th total of 6,154,705 shares. Based on an average trading volume of 3,578,336 shares, the short-interest ratio is currently 2.7 days. Approximately 19.3% of the company's shares are short sold. View Viking Therapeutics' Current Options Chain. Who are some of Viking Therapeutics' key competitors? Some companies that are related to Viking Therapeutics include TESARO (TSRO), Akcea Therapeutics (AKCA), Clovis Oncology (CLVS), Spectrum Pharmaceuticals (SPPI), Endo International (ENDP), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Akorn (AKRX), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Myokardia (MYOK), Puma Biotechnology (PBYI) and Prestige Brands (PBH). Who are Viking Therapeutics' key executives? Viking Therapeutics' management team includes the folowing people: Dr. Brian Lian, Pres, CEO & Director (Age 52)Mr. Michael Morneau, CFO & Principal Accounting Officer (Age 53)Mr. Gregory S. Zante CPA, VP of Fin. & Operations (Age 47)Ms. Amy Broidrick, Sr. VP of Corp. Devel.Dr. Hiroko Masamune Ph.D., Sr. VP of Pharmaceutical Devel. (Age 61) When did Viking Therapeutics IPO? (VKTX) raised $20 million in an initial public offering on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager. Has Viking Therapeutics been receiving favorable news coverage? News coverage about VKTX stock has been trending positive on Wednesday, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Viking Therapeutics earned a media sentiment score of 0.46 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.22 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. Who are Viking Therapeutics' major shareholders? Viking Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.10%). Company insiders that own Viking Therapeutics stock include J Matthew Singleton, Lawson Macartney, Matthew W Foehr and Michael Morneau. View Institutional Ownership Trends for Viking Therapeutics. Which major investors are buying Viking Therapeutics stock? VKTX stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have bought Viking Therapeutics stock in the last two years include J Matthew Singleton, Lawson Macartney and Matthew W Foehr. View Insider Buying and Selling for Viking Therapeutics. How do I buy shares of Viking Therapeutics? Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Viking Therapeutics' stock price today? One share of VKTX stock can currently be purchased for approximately $9.95. How big of a company is Viking Therapeutics? Viking Therapeutics has a market capitalization of $651.41 million. The biotechnology company earns $-20,570,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Viking Therapeutics employs 14 workers across the globe. How can I contact Viking Therapeutics? Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected] MarketBeat Community Rating for Viking Therapeutics (NASDAQ VKTX)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 197 (Vote Outperform)Underperform Votes: 119 (Vote Underperform)Total Votes: 316MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe VKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?